Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 4/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24853959 | 0.92 | SLC6A4 (0.37) | HTR6HTR2AHTR2CHTR2BHRH1 | |
| SCHEMBL24775357 | 0.86 | SLC6A2 (0.35) | SIGMAR1CHRNA7SLC6A2SLC6A3 | |
| SCHEMBL24775061 | 0.85 | CHRNA7 (0.35) | HTR1ACHRNA7DRD2 | |
| SCHEMBL24774767 | 0.83 | LIPG (0.38) | HTR1ASIGMAR1CHRNA7DRD2BCHE | |
| SCHEMBL23323081 | 0.82 | CHRNB2 (0.47) | TAAR1HTR6CHRNA7 | |
| SCHEMBL24775073 | 0.82 | RIPK1 (0.38) | CHRNA7 | |
| SCHEMBL24774831 | 0.81 | RIPK1 (0.38) | CHRNA7 | |
| SCHEMBL24854069 | 0.80 | CHRNA7 (0.35) | HTR6CHRNA7BCHE | |
| SCHEMBL24774830 | 0.78 | CHRNA7 (0.34) | CHRNA7 | |
| SCHEMBL24775456 | 0.77 | HSP90AA1 (0.44) | HTR2CCHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | TAAR1 4675/4885HTR6 3133/4885HTR2A 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.